Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care

Overview:
Triple-negative breast cancer (TNBC) is a rare and aggressive form of breast cancer with well-documented disparities among Black and Hispanic women in terms of incidence rates, stage at diagnosis, and treatment outcomes. Rapid advances and novel therapies are redefining treatment paradigms, and it is critical to consider emerging data in the context of these disparities to ensure improved outcomes reach all patients.

The Reflective Case-Based Oncology Collective combines a core curriculum developed by renowned experts in breast cancer with real-world cases that challenge learners to reflect on the application of the evidence to their own clinical practice, bringing together physicians to collectively consider the ramifications for care of new approaches to treatment and clinical management of metastatic TNBC.

Learning Objectives:
Upon completion of this activity, participants will be able to:

• Explain disparities in diagnosis, treatment, and outcomes among diverse populations of patients with triple negative breast cancer (TNBC), and potential root causes including biologic and environmental factors
• Identify strategies to overcome disparities in diagnosis, testing, and treatment for patients with TNBC, including strategies to broaden access to and enrollment in clinical trials
• Evaluate results from pivotal clinical trials evaluating the efficacy and safety of current and investigational treatments for patients with TNBC
• Integrate practice-changing data into treatment plans for patients with TNBC to improve outcomes across diverse racial, ethnic, and socioeconomic patient populations

Target Audience:
This educational activity is directed towards community physicians, APPs, nurses, and pharmacists who treat patients with breast cancer.

Faculty:

Gregory Vidal and Erika Hamilton

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.